Hutchison China Meditech is the holding company of a pharmaceutical and healthcare group based primarily in China. Chi-Med is a subsidiary of Hutchison Whampoa Ltd. ("HWL"), an international corporation listed on the Main Board of the Hong Kong Stock Exchange which had an annual turnover of approximately US$45 billion in 2008 and approximately 220, 000 employees in 54 countries worldwide as at 31 December 2008.

Chi-Med focuses on researching, developing, manufacturing and selling pharmaceuticals, and health oriented consumer products. Chi-Med was established in 2000 as a wholly-owned subsidiary of HWL when HWL identified three business development opportunities related to Traditional Chinese Medicine ("TCM"). These were drug research and development, China healthcare and consumer products. The overall aim of Chi-Med is to draw on the untapped wealth of knowledge and history of usage in the TCM industry to develop pharmaceutical and consumer products for the global market. Chi-Med's three businesses complement each other in pursuit of this aim.

Since establishment, Chi-Med has expanded beyond its base TCM business into the research and development of small molecule drugs as well as the expansion of health oriental consumer products.